- Conditions
- Hypochondroplasia
- Interventions
- Not listed
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 30 Months to 16 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pancreatic Cancer
- Interventions
- protein expression analysis, western blotting, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
- Interventions
- Infigratinib, Placebo
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 47
- States / cities
- Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Epigallocatechin-3-gallate (EGCG)
- Drug
- Lead sponsor
- Hal Chapman
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Kidney Diseases, Chronic Heart Failure, Iron Deficiency Anemia
- Interventions
- Iron Sucrose
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Tumor or Lymphoma
- Interventions
- JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3, JNJ-42756493: Part 4
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 20 more
- Conditions
- Advanced Solid Tumor
- Interventions
- BG-C137, Anticancer Agents
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Rochester, Minnesota + 3 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
- Interventions
- [203Pb]Pb-PSV359, [212Pb]Pb-PSV359
- Drug
- Lead sponsor
- Perspective Therapeutics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 11
- States / cities
- Miami, Florida • Kansas City, Kansas • Lexington, Kentucky + 7 more
- Conditions
- Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Interventions
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cancer
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Teresa Helsten, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- La Jolla, California • Chicago, Illinois
- Conditions
- Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Interventions
- [18F]FAPI-74 PET/CT
- Drug
- Lead sponsor
- SOFIE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 16
- States / cities
- Cerritos, California • Duarte, California • Irvine, California + 12 more
- Conditions
- PDAC - Pancreatic Ductal Adenocarcinoma, FAP
- Interventions
- [68Ga]FAPI-46
- Drug
- Lead sponsor
- SOFIE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Rochester, Minnesota + 1 more
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Duarte, California • Stanford, California + 6 more
- Conditions
- Advanced Chronic Liver Disease, Healthy Participants
- Interventions
- AZD2389, Quinidine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Restrictive Scar Contracture, Restrictive Hypertrophic Scar, Burn Scar Contractures, Burn Scar
- Interventions
- ICX-RHY-013
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Interventions
- Vepugratinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Myrtle Beach, South Carolina
- Conditions
- Colorectal Cancer
- Interventions
- monoclonal antibody F19, iodine I 131 monoclonal antibody F19
- Biological · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • New York, New York
- Conditions
- Cancer, Skin Fibroblasts, Muscle Weakness
- Interventions
- Nicotinamide Riboside (NR)
- Dietary Supplement
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Gastric Cancer, Cholangiocarcinoma, Bladder Cancer
- Interventions
- [18F]FAPI-74, [18F]FDG
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
- Interventions
- Futibatinib, Futibatinib plus Fulvestrant
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • San Francisco, California • Fort Myers, Florida + 12 more
- Conditions
- Gingival Recession
- Interventions
- Gintuit, Autologous palatal tissue
- Device · Other
- Lead sponsor
- Organogenesis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas + 1 more
- Conditions
- X-linked Hypophosphatemia
- Interventions
- burosumab
- Biological
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 1 more
- Conditions
- Pancreatic Adenocarcinoma Metastatic
- Interventions
- OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg)
- Drug
- Lead sponsor
- Oncomatryx Biopharma S.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma
- Interventions
- [18F]FAPI-74 PET/CT
- Drug
- Lead sponsor
- SOFIE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more